The novel tuberculosis vaccine, AERAS-402, induces robust and polyfunctional CD4+ and CD8+ T cells in adults.
暂无分享,去创建一个
M. Tameris | M. Hatherill | J. McClain | G. Hussey | W. Hanekom | H. Mahomed | J. Sadoff | G. Weverling | J. Goudsmit | M. Pau | A. Hawkridge | L. van der Merwe | M. de Kock | D. Sizemore | D. Abrahams | B. Abel | J. Hendriks | Lebohang Makhethe | Mzwandile Erasmus | N. Mansoor | S. Gelderbloem | A. Veldsman | Giulia Schirru | Jacqueline Gearhart | J. Hughes | M. Goetz | M. D. Kock
[1] J. Dietrich,et al. Protection and Polyfunctional T Cells Induced by Ag85B-TB10.4/IC31® against Mycobacterium tuberculosis Is Highly Dependent on the Antigen Dose , 2009, PloS one.
[2] H. McShane,et al. Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A , 2009, PloS one.
[3] A. Lemckert,et al. Heterologous prime–boost vaccinations for poverty-related diseases: advantages and future prospects , 2009, Expert review of vaccines.
[4] D. H. Young,et al. Mucosal immune responses to HIV-1 in elite controllers: a potential correlate of immune control. , 2009, Blood.
[5] William R. Jacobs,et al. A Critical Role for CD8 T Cells in a Nonhuman Primate Model of Tuberculosis , 2009, PLoS pathogens.
[6] D. Mehrotra,et al. Safety and immunogenicity of adenovirus-vectored near-consensus HIV type 1 clade B gag vaccines in healthy adults. , 2009, AIDS research and human retroviruses.
[7] J. Andersson,et al. rBCG Induces Strong Antigen-Specific T Cell Responses in Rhesus Macaques in a Prime-Boost Setting with an Adenovirus 35 Tuberculosis Vaccine Vector , 2008, PloS one.
[8] H. Dockrell,et al. A comparison of IFNgamma detection methods used in tuberculosis vaccine trials. , 2008, Tuberculosis.
[9] A. Hill,et al. Multifunctional, High-Level Cytokine-Producing Th1 Cells in the Lung, but Not Spleen, Correlate with Protection against Mycobacterium tuberculosis Aerosol Challenge in Mice , 2008, The Journal of Immunology.
[10] D. Woodland,et al. Early T‐cell responses in tuberculosis immunity , 2008, Immunological reviews.
[11] T. Lang,et al. Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa. , 2008, The Journal of infectious diseases.
[12] R. Adegbola,et al. Safety and Immunogenicity of the Candidate Tuberculosis Vaccine MVA85A in West Africa , 2008, PloS one.
[13] V. A. Stewart,et al. Adenovirus 5 and 35 vectors expressing Plasmodium falciparum circumsporozoite surface protein elicit potent antigen-specific cellular IFN-gamma and antibody responses in mice. , 2008, Vaccine.
[14] R. Wilkinson,et al. Distinct, Specific IL-17- and IL-22-Producing CD4+ T Cell Subsets Contribute to the Human Anti-Mycobacterial Immune Response1 , 2008, The Journal of Immunology.
[15] David A. Price,et al. Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover , 2007, The Journal of experimental medicine.
[16] S. Kaufmann,et al. Poor correlation between BCG vaccination-induced T cell responses and protection against tuberculosis , 2007, Proceedings of the National Academy of Sciences.
[17] Mario Roederer,et al. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major , 2007, Nature Medicine.
[18] T. van der Poll,et al. Protective Immune Responses to a Recombinant Adenovirus Type 35 Tuberculosis Vaccine in Two Mouse Strains: CD4 and CD8 T-Cell Epitope Mapping and Role of Gamma Interferon , 2007, Infection and Immunity.
[19] N. Letvin,et al. Effect of Preexisting Immunity to Adenovirus Human Serotype 5 Antigens on the Immune Responses of Nonhuman Primates to Vaccine Regimens Based on Human- or Chimpanzee-Derived Adenovirus Vectors , 2007, Journal of Virology.
[20] B. Ryffel,et al. Tumor necrosis factor is critical to control tuberculosis infection. , 2007, Microbes and infection.
[21] S. Nakae,et al. IL-17-Mediated Regulation of Innate and Acquired Immune Response against Pulmonary Mycobacterium bovis Bacille Calmette-Guérin Infection1 , 2007, The Journal of Immunology.
[22] V. A. Stewart,et al. Priming with an Adenovirus 35-Circumsporozoite Protein (CS) Vaccine followed by RTS,S/AS01B Boosting Significantly Improves Immunogenicity to Plasmodium falciparum CS Compared to That with Either Malaria Vaccine Alone , 2007, Infection and Immunity.
[23] M. Havenga,et al. Immunogenicity of Heterologous Recombinant Adenovirus Prime-Boost Vaccine Regimens Is Enhanced by Circumventing Vector Cross-Reactivity , 2006, Journal of Virology.
[24] M. Havenga,et al. Novel replication-incompetent adenoviral B-group vectors: high vector stability and yield in PER.C6 cells. , 2006, The Journal of general virology.
[25] Mario Roederer,et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. , 2006, Blood.
[26] A. Tyznik,et al. Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells , 2006, Nature.
[27] J. Sadoff,et al. Advances in tuberculosis vaccine strategies , 2006, Nature Reviews Microbiology.
[28] C. Dye,et al. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness , 2006, The Lancet.
[29] B. Berkhout,et al. Immunogenicity and Protection of a Recombinant Human Adenovirus Serotype 35-Based Malaria Vaccine against Plasmodium yoelii in Mice , 2006, Infection and Immunity.
[30] H. Vordermeier,et al. Recent advances in the development of adenovirus- and poxvirus-vectored tuberculosis vaccines. , 2005, Current gene therapy.
[31] M. Lifton,et al. Immunogenicity of Heterologous Prime-Boost Regimens Involving Recombinant Adenovirus Serotype 11 (Ad11) and Ad35 Vaccine Vectors in the Presence of Anti-Ad5 Immunity , 2005, Journal of Virology.
[32] Z. Xing,et al. Single Mucosal, but Not Parenteral, Immunization with Recombinant Adenoviral-Based Vaccine Provides Potent Protection from Pulmonary Tuberculosis1 , 2004, The Journal of Immunology.
[33] H. McShane,et al. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans , 2004, Nature Medicine.
[34] P. Haslett,et al. Novel application of a whole blood intracellular cytokine detection assay to quantitate specific T-cell frequency in field studies. , 2004, Journal of immunological methods.
[35] B. Berkhout,et al. Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector , 2004, AIDS.
[36] S. Kostense,et al. Immunogenicity of Recombinant Adenovirus Serotype 35 Vaccine in the Presence of Pre-Existing Anti-Ad5 Immunity1 , 2004, The Journal of Immunology.
[37] Jaap Goudsmit,et al. Quantifying Adenovirus-Neutralizing Antibodies by Luciferase Transgene Detection: Addressing Preexisting Immunity to Vaccine and Gene Therapy Vectors , 2003, Journal of Clinical Microbiology.
[38] H. McShane,et al. Enhanced Immunogenicity of CD4+ T-Cell Responses and Protective Efficacy of a DNA-Modified Vaccinia Virus Ankara Prime-Boost Vaccination Regimen for Murine Tuberculosis , 2001, Infection and Immunity.
[39] P. Andersen,et al. Control of latent Mycobacterium tuberculosis infection is dependent on CD8 T cells , 2000, European journal of immunology.
[40] J. Sedgwick,et al. Structural deficiencies in granuloma formation in TNF gene-targeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection, which is not compensated for by lymphotoxin. , 1999, Journal of immunology.
[41] J. Casanova,et al. Novel human immunodeficiencies reveal the essential role of type-I cytokines in immunity to intracellular bacteria. , 1998, Immunology today.
[42] S. Kaufmann,et al. Mycobacterium bovis Bacille Calmette-Guérin strains secreting listeriolysin of Listeria monocytogenes. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[43] C. Lowenstein,et al. Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. , 1995, Immunity.
[44] V. Diwan,et al. Protective effect of BCG against tuberculous meningitis and miliary tuberculosis: a meta-analysis. , 1993, International journal of epidemiology.
[45] J. Flynn,et al. An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection , 1993, The Journal of experimental medicine.
[46] J. Abrams,et al. Cytokine secretion by CD4 T lymphocytes acquired in response to Mycobacterium tuberculosis infection. , 1993, Journal of immunology.
[47] S. Kaufmann,et al. Apoptotic vesicles crossprime CD8 T cells and protect against tuberculosis. , 2006, Immunity.
[48] S. Behar,et al. Mycobacterium tuberculosis-specific CD8+ T cells and their role in immunity. , 2006, Critical reviews in immunology.
[49] P. Fine,et al. Issues relating to the use of BCG in immunization programmes A discussion document , 1999 .
[50] G. Kaplan,et al. rhuIL-2 adjunctive therapy in multidrug resistant tuberculosis: a comparison of two treatment regimens and placebo. , 1997, Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.